Research map: Ustekinumab for the treatment of psoriasis: a well-established therapy primed for resurgence

Back to the article

Papers in this map

  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials · Richard G B Langley · 2014 · 2005 citations · Cited by this paper
  2. The role of immunosenescence and chronic medical conditions on the immune response to respiratory syncytial virus in older individuals · 2026 · Related
  3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) · Craig L. Leonardi · 2008 · 1876 citations · Cited by this paper
  4. Harnessing the immune system in lung cancer: emerging role of the microbiome · 2026 · Related
  5. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways · Rajan P. Nair · 2009 · 1428 citations · Cited by this paper
  6. Organ damage in systemic sclerosis: linking immune activation, vasculopathy, and fibrosis to precision treatment · 2026 · Related
  7. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) · Kim Alexander Papp · 2008 · 1365 citations · Cited by this paper
  8. Beyond the binary: understanding inflammatory bowel disease in the context of HIV-induced immunodeficiency · 2026 · Related
  9. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics · Alan Menter · 2019 · 971 citations · Cited by this paper
  10. Inflammatory bowel disease and primary sclerosing cholangitis: immunological links and clinical outlook · 2026 · Related
  11. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis · Christopher E.M. Griffiths · 2010 · 858 citations · Cited by this paper
  12. Keratoconus: an ocular manifestation of systemic immune dysregulation? · 2026 · Related
  13. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis · Mark Lebwohl · 2015 · 829 citations · Cited by this paper
  14. Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis · 2026 · Related
  15. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial · Iain B. McInnes · 2013 · 806 citations · Cited by this paper
  16. Reconsidering the interpretation of polyautoimmunity in chronic immune-mediated neuropathies: association, misclassification, and clinical implications · 2026 · Related
  17. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial · Kristian Reich · 2017 · 767 citations · Cited by this paper
  18. Malignancies in the context of Inborn errors of immunity: an immunologist’s view · 2026 · Related
  19. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials · Kenneth B. Gordon · 2018 · 683 citations · Cited by this paper
  20. Sarcoid-like reactions: a comprehensive review of granulomatous diseases mimicking sarcoidosis · 2026 · Related
  21. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial · Christopher T. Ritchlin · 2014 · 664 citations · Cited by this paper
  22. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial · Diamant Thaçi · 2015 · 551 citations · Cited by this paper
  23. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines · Erin Fitch · 2007 · 415 citations · Cited by this paper
  24. Discovery and mechanism of ustekinumab · Jacqueline Benson · 2011 · 343 citations · Cited by this paper
  25. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial · Richard G B Langley · 2017 · 343 citations · Cited by this paper
  26. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial · Kristian Reich · 2021 · 315 citations · Cited by this paper
  27. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study · Andrew Blauvelt · 2016 · 312 citations · Cited by this paper
  28. Comparison of Biologics and Oral Treatments for Plaque Psoriasis · April Wang Armstrong · 2020 · 294 citations · Cited by this paper
  29. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease · Lin Sun · 2015 · 238 citations · Cited by this paper
  30. Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up · Richard G B Langley · 2014 · 206 citations · Cited by this paper
  31. IL-12 protects from psoriasiform skin inflammation · Paulina Kulig · 2016 · 196 citations · Cited by this paper
  32. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study · Kristian Reich · 2017 · 193 citations · Cited by this paper
  33. A novel IL‐23p19/Ebi3 (IL‐39) cytokine mediates inflammation in Lupus‐like mice · Xiaoqian Wang · 2016 · 173 citations · Cited by this paper
  34. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response · L. Sawyer · 2019 · 162 citations · Cited by this paper
  35. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials · Kenneth B. Gordon · 2011 · 142 citations · Cited by this paper
  36. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years · Alexa B. Kimball · 2012 · 134 citations · Cited by this paper
  37. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study · Carle F. Paul · 2018 · 104 citations · Cited by this paper
  38. Novel IL27p28/IL12p40 Cytokine Suppressed Experimental Autoimmune Uveitis by Inhibiting Autoreactive Th1/Th17 Cells and Promoting Expansion of Regulatory T Cells · Renxi Wang · 2012 · 92 citations · Cited by this paper
  39. Targeting IL-23 in psoriasis: current perspectives · Christina Fotiadou · 2018 · 91 citations · Cited by this paper

Source: OpenAlex (CC0)